Sandbox:Preeti: Difference between revisions
Jump to navigation
Jump to search
Preeti Singh (talk | contribs) No edit summary |
Preeti Singh (talk | contribs) No edit summary |
||
Line 8: | Line 8: | ||
! rowspan="2" |Pathophysiology | ! rowspan="2" |Pathophysiology | ||
! rowspan="2" |Symptoms | ! rowspan="2" |Symptoms | ||
! rowspan="2" |Physical Examination | ! rowspan="2" |Physical Examination | ||
! colspan="3" |Laboratory Findings | ! colspan="3" |Laboratory Findings | ||
Line 17: | Line 16: | ||
|- | |- | ||
| | | | ||
|[[Diffuse large B-cell lymphoma]]<ref name="Shipp2002">{{cite journal |doi=10.1038/nm0102-68 |pmid=11786909 |title=Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning |journal=Nature Medicine |volume=8 |issue=1 |pages=68–74 |year=2002 |last1=Shipp |first1=Margaret A. |last2=Ross |first2=Ken N. |last3=Tamayo |first3=Pablo |last4=Weng |first4=Andrew P. |last5=Kutok |first5=Jeffery L. |last6=Aguiar |first6=Ricardo C.T. |last7=Gaasenbeek |first7=Michelle |last8=Angelo |first8=Michael |last9=Reich |first9=Michael |last10=Pinkus |first10=Geraldine S. |last11=Ray |first11=Tane S. |last12=Koval |first12=Margaret A. |last13=Last |first13=Kim W. |last14=Norton |first14=Andrew |last15=Lister |first15=T. Andrew |last16=Mesirov |first16=Jill |last17=Neuberg |first17=Donna S. |last18=Lander |first18=Eric S. |last19=Aster |first19=Jon C. |last20=Golub |first20=Todd R. }}</ref><ref name="Rosenwald2002">{{cite journal |doi=10.1056/NEJMoa012914 |pmid=12075054 |title=The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma |journal=New England Journal of Medicine |volume=346 |issue=25 |pages=1937–47 |year=2002 |last1=Rosenwald |first1=Andreas |last2=Wright |first2=George |last3=Chan |first3=Wing C. |last4=Connors |first4=Joseph M. |last5=Campo |first5=Elias |last6=Fisher |first6=Richard I. |last7=Gascoyne |first7=Randy D. |last8=Muller-Hermelink |first8=H. Konrad |last9=Smeland |first9=Erlend B. |last10=Giltnane |first10=Jena M. |last11=Hurt |first11=Elaine M. |last12=Zhao |first12=Hong |last13=Averett |first13=Lauren |last14=Yang |first14=Liming |last15=Wilson |first15=Wyndham H. |last16=Jaffe |first16=Elaine S. |last17=Simon |first17=Richard |last18=Klausner |first18=Richard D. |last19=Powell |first19=John |last20=Duffey |first20=Patricia L. |last21=Longo |first21=Dan L. |last22=Greiner |first22=Timothy C. |last23=Weisenburger |first23=Dennis D. |last24=Sanger |first24=Warren G. |last25=Dave |first25=Bhavana J. |last26=Lynch |first26=James C. |last27=Vose |first27=Julie |last28=Armitage |first28=James O. |last29=Montserrat |first29=Emilio |last30=López-Guillermo |first30=Armando |display-authors=29 }}</ref><ref name="Colomo2003">{{cite journal |doi=10.1182/blood-2002-04-1286 |pmid=12393466 |title=Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma |journal=Blood |volume=101 |issue=1 |pages=78–84 |year=2002 |last1=Colomo |first1=L. |last2=López-Guillermo |first2=A |last3=Perales |first3=M |last4=Rives |first4=S |last5=Martínez |first5=A |last6=Bosch |first6=F |last7=Colomer |first7=D |last8=Falini |first8=B |last9=Montserrat |first9=E |last10=Campo |first10=E }}</ref><ref name="”seer”">National Cancer Institute. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov</ref><ref>Tilly H, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2015; 26: v116-v125</ref><ref name="”seer”2">National Cancer Institute. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov</ref><ref name="pmid27271843">{{cite journal| author=Korkolopoulou P, Vassilakopoulos T, Milionis V, Ioannou M| title=Recent Advances in Aggressive Large B-cell Lymphomas: A Comprehensive Review. | journal=Adv Anat Pathol | year= 2016 | volume= 23 | issue= 4 | pages= 202-43 | pmid=27271843 | doi=10.1097/PAP.0000000000000117 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27271843 }}</ref> | |[[Diffuse large B-cell lymphoma]]]<ref name="Shipp2002">{{cite journal |doi=10.1038/nm0102-68 |pmid=11786909 |title=Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning |journal=Nature Medicine |volume=8 |issue=1 |pages=68–74 |year=2002 |last1=Shipp |first1=Margaret A. |last2=Ross |first2=Ken N. |last3=Tamayo |first3=Pablo |last4=Weng |first4=Andrew P. |last5=Kutok |first5=Jeffery L. |last6=Aguiar |first6=Ricardo C.T. |last7=Gaasenbeek |first7=Michelle |last8=Angelo |first8=Michael |last9=Reich |first9=Michael |last10=Pinkus |first10=Geraldine S. |last11=Ray |first11=Tane S. |last12=Koval |first12=Margaret A. |last13=Last |first13=Kim W. |last14=Norton |first14=Andrew |last15=Lister |first15=T. Andrew |last16=Mesirov |first16=Jill |last17=Neuberg |first17=Donna S. |last18=Lander |first18=Eric S. |last19=Aster |first19=Jon C. |last20=Golub |first20=Todd R. }}</ref><ref name="Rosenwald2002">{{cite journal |doi=10.1056/NEJMoa012914 |pmid=12075054 |title=The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma |journal=New England Journal of Medicine |volume=346 |issue=25 |pages=1937–47 |year=2002 |last1=Rosenwald |first1=Andreas |last2=Wright |first2=George |last3=Chan |first3=Wing C. |last4=Connors |first4=Joseph M. |last5=Campo |first5=Elias |last6=Fisher |first6=Richard I. |last7=Gascoyne |first7=Randy D. |last8=Muller-Hermelink |first8=H. Konrad |last9=Smeland |first9=Erlend B. |last10=Giltnane |first10=Jena M. |last11=Hurt |first11=Elaine M. |last12=Zhao |first12=Hong |last13=Averett |first13=Lauren |last14=Yang |first14=Liming |last15=Wilson |first15=Wyndham H. |last16=Jaffe |first16=Elaine S. |last17=Simon |first17=Richard |last18=Klausner |first18=Richard D. |last19=Powell |first19=John |last20=Duffey |first20=Patricia L. |last21=Longo |first21=Dan L. |last22=Greiner |first22=Timothy C. |last23=Weisenburger |first23=Dennis D. |last24=Sanger |first24=Warren G. |last25=Dave |first25=Bhavana J. |last26=Lynch |first26=James C. |last27=Vose |first27=Julie |last28=Armitage |first28=James O. |last29=Montserrat |first29=Emilio |last30=López-Guillermo |first30=Armando |display-authors=29 }}</ref><ref name="Colomo2003">{{cite journal |doi=10.1182/blood-2002-04-1286 |pmid=12393466 |title=Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma |journal=Blood |volume=101 |issue=1 |pages=78–84 |year=2002 |last1=Colomo |first1=L. |last2=López-Guillermo |first2=A |last3=Perales |first3=M |last4=Rives |first4=S |last5=Martínez |first5=A |last6=Bosch |first6=F |last7=Colomer |first7=D |last8=Falini |first8=B |last9=Montserrat |first9=E |last10=Campo |first10=E }}</ref><ref name="”seer”">National Cancer Institute. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov</ref><ref>Tilly H, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2015; 26: v116-v125</ref><ref name="”seer”2">National Cancer Institute. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov</ref><ref name="pmid27271843">{{cite journal| author=Korkolopoulou P, Vassilakopoulos T, Milionis V, Ioannou M| title=Recent Advances in Aggressive Large B-cell Lymphomas: A Comprehensive Review. | journal=Adv Anat Pathol | year= 2016 | volume= 23 | issue= 4 | pages= 202-43 | pmid=27271843 | doi=10.1097/PAP.0000000000000117 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27271843 }}</ref> | ||
|Classified into 2 subtypes based on [[gene expression]] profiles: | |Classified into 2 subtypes based on [[gene expression]] profiles: | ||
*Germinal centre B-cell-like (GCB) | *Germinal centre B-cell-like (GCB) | ||
Line 37: | Line 36: | ||
: | : | ||
* | * | ||
| | | | ||
* Non tender mass | * Non tender mass | ||
Line 86: | Line 84: | ||
*[[Dyspnea]] | *[[Dyspnea]] | ||
*Painless swelling in the neck, axilla, groin, thorax and abdomen | *Painless swelling in the neck, axilla, groin, thorax and abdomen | ||
| | | | ||
* [[Lymphadenopathy|Central and peripheral lymphadenopathy]] | * [[Lymphadenopathy|Central and peripheral lymphadenopathy]] | ||
Line 99: | Line 96: | ||
|- | |- | ||
| | | | ||
|[[ | |[[Burkitt lymphoma]] | ||
| | | | ||
* Translocation of chromosome 8 ''[[myc]]'' locus with 3 possible partners (accounting for 90% of translocations): | * Translocation of chromosome 8 ''[[myc]]'' locus with 3 possible partners (accounting for 90% of translocations): | ||
Line 110: | Line 107: | ||
* Unexplained [[weight loss]] | * Unexplained [[weight loss]] | ||
* [[Swollen lymph nodes]] in the neck, axilla, or groin | * [[Swollen lymph nodes]] in the neck, axilla, or groin | ||
| | | | ||
* [[Proptosis]] | * [[Proptosis]] | ||
Line 150: | Line 146: | ||
* Abdominal distention | * Abdominal distention | ||
* Fatigue | * Fatigue | ||
* Night sweats | |||
* Weight Loss | |||
* Extranodal involvement of gastrointtestinal (GI) tract, lungs, and central nervous system (CNS) | * Extranodal involvement of gastrointtestinal (GI) tract, lungs, and central nervous system (CNS) | ||
| | | | ||
* Generalized lymphadenopathy | * Generalized lymphadenopathy | ||
Line 189: | Line 184: | ||
** Abdominal pain | ** Abdominal pain | ||
** Hemorrhage | ** Hemorrhage | ||
* Chronic infectious conditions or autoimmune processes, such as | * Chronic infectious conditions or autoimmune processes, such as | ||
** ''H pylori'' gastritis | ** ''H pylori'' gastritis | ||
Line 208: | Line 202: | ||
** Deletion 7q21-32 | ** Deletion 7q21-32 | ||
** Translocations of the CDK6 gene located at 7q21. | ** Translocations of the CDK6 gene located at 7q21. | ||
| | | | ||
| | | | ||
Line 243: | Line 236: | ||
* Recurrent [[Infection|infections]] | * Recurrent [[Infection|infections]] | ||
* Early satiety | * Early satiety | ||
| | | | ||
* [[Pallor]], | * [[Pallor]], | ||
Line 273: | Line 262: | ||
|- | |- | ||
|[[Multiple myeloma|Plasma cell myeloma]] | |[[Multiple myeloma|Plasma cell myeloma]] | ||
| | | | ||
| | | | ||
Line 282: | Line 270: | ||
|- | |- | ||
|[[Chronic lymphocytic leukemia]] / [[Chronic lymphocytic leukemia|small lymphocytic lymphoma]] | |[[Chronic lymphocytic leukemia]] / [[Chronic lymphocytic leukemia|small lymphocytic lymphoma]] | ||
| | | | ||
| | | | ||
Line 291: | Line 278: | ||
|- | |- | ||
|[[Monoclonal B-cell lymphocytosis]] | |[[Monoclonal B-cell lymphocytosis]] | ||
| | | | ||
| | | | ||
Line 300: | Line 286: | ||
|- | |- | ||
|[[B-cell prolymphocytic leukemia]] | |[[B-cell prolymphocytic leukemia]] | ||
| | | | ||
| | | | ||
Line 309: | Line 294: | ||
|- | |- | ||
|[[Waldenström's macroglobulinemia|Waldenström's macroglubulinemia]] | |[[Waldenström's macroglobulinemia|Waldenström's macroglubulinemia]] | ||
| | | | ||
| | | | ||
Line 318: | Line 302: | ||
|- | |- | ||
|[[Monoclonal gammopathy of undetermined significance]] (MGUS) | |[[Monoclonal gammopathy of undetermined significance]] (MGUS) | ||
| | | | ||
| | | | ||
Line 327: | Line 310: | ||
|- | |- | ||
|[[Heavy chain disease]] | |[[Heavy chain disease]] | ||
| | | | ||
| | | | ||
Line 336: | Line 318: | ||
|- | |- | ||
|Solitary plasmacytoma of bone | |Solitary plasmacytoma of bone | ||
| | | | ||
| | | | ||
Line 345: | Line 326: | ||
|- | |- | ||
|Extraosseous plasmacytoma | |Extraosseous plasmacytoma | ||
| | | | ||
| | | | ||
Line 354: | Line 334: | ||
|- | |- | ||
|Monoclonal immunoglobulin deposition diseases | |Monoclonal immunoglobulin deposition diseases | ||
| | | | ||
| | | | ||
Line 363: | Line 342: | ||
|- | |- | ||
|Extranodal marginal zone lymphoma of [[MALT lymphoma|mucosa-associated lymphoid tissue]] (MALT lymphoma) | |Extranodal marginal zone lymphoma of [[MALT lymphoma|mucosa-associated lymphoid tissue]] (MALT lymphoma) | ||
| | | | ||
| | | | ||
Line 372: | Line 350: | ||
|- | |- | ||
|Large B-cell lymphoma with IRF4 rearrangement | |Large B-cell lymphoma with IRF4 rearrangement | ||
| | | | ||
| | | | ||
Line 381: | Line 358: | ||
|- | |- | ||
|[[Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle center lymphoma]] | |[[Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle center lymphoma]] | ||
| | | | ||
| | | | ||
Line 390: | Line 366: | ||
|- | |- | ||
|T-cell/histiocyte-rich large B-cell lymphoma | |T-cell/histiocyte-rich large B-cell lymphoma | ||
| | | | ||
| | | | ||
Line 399: | Line 374: | ||
|- | |- | ||
|[[Lymphomatoid granulomatosis]] | |[[Lymphomatoid granulomatosis]] | ||
| | | | ||
| | | | ||
Line 408: | Line 382: | ||
|- | |- | ||
|[[Primary mediastinal large B-cell lymphoma|Primary mediastinal (thymic) large B-cell lymphoma]] | |[[Primary mediastinal large B-cell lymphoma|Primary mediastinal (thymic) large B-cell lymphoma]] | ||
| | | | ||
| | | | ||
Line 417: | Line 390: | ||
|- | |- | ||
|[[Intravascular large B-cell lymphoma]] | |[[Intravascular large B-cell lymphoma]] | ||
| | | | ||
| | | | ||
Line 426: | Line 398: | ||
|- | |- | ||
|ALK1 large B-cell lymphoma | |ALK1 large B-cell lymphoma | ||
| | | | ||
| | | | ||
Line 435: | Line 406: | ||
|- | |- | ||
|Plasmablastic lymphoma | |Plasmablastic lymphoma | ||
| | | | ||
| | | | ||
Line 444: | Line 414: | ||
|- | |- | ||
|[[Primary effusion lymphoma]] | |[[Primary effusion lymphoma]] | ||
| | | | ||
| | | | ||
Line 453: | Line 422: | ||
|- | |- | ||
|High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements | |High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements | ||
| | | | ||
| | | | ||
Line 478: | Line 446: | ||
* [[Anemia]] | * [[Anemia]] | ||
* May progress to [[Sezary syndrome]] (Skin involvement plus hematogenous dissemination) | * May progress to [[Sezary syndrome]] (Skin involvement plus hematogenous dissemination) | ||
| | | | ||
* Cutaneous manifestaions | * Cutaneous manifestaions | ||
Line 485: | Line 452: | ||
| | | | ||
|- | |- | ||
| | | | ||
| | | | ||
Line 494: | Line 460: | ||
| | | | ||
|- | |- | ||
| | | | ||
| | | | ||
Line 503: | Line 468: | ||
| | | | ||
|- | |- | ||
| | | | ||
| | | | ||
Line 527: | Line 491: | ||
* [[Bone pain]] | * [[Bone pain]] | ||
* [[Dyspnea]] | * [[Dyspnea]] | ||
| | | | ||
* Usually appear pale and malnourished. | * Usually appear pale and malnourished. | ||
Line 550: | Line 513: | ||
|- | |- | ||
|[[Subcutaneous panniculitis-like T-cell lymphoma]] | |[[Subcutaneous panniculitis-like T-cell lymphoma]] | ||
| | | | ||
| | | |
Revision as of 15:08, 27 December 2018
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Preeti Singh, M.B.B.S.[2]
Pathophysiology | Symptoms | Physical Examination | Laboratory Findings | ||||
---|---|---|---|---|---|---|---|
Immunochemistry | Blood work | Biospy | |||||
Diffuse large B-cell lymphoma][1][2][3][4][5][6][7] | Classified into 2 subtypes based on gene expression profiles:
|
|
|
|
|
Centroblastic
Immunoblastic::
Anaplastic:
| |
Follicular lymphoma |
|
|
|||||
Burkitt lymphoma |
|
|
|
| |||
B cell lymphoma | Mantle cell lymphoma |
|
|
|
|
CBC
|
|
Nodal marginal zone B-cell lymphoma |
|
|
|
| |||
Splenic marginal zone lymphoma |
|
| |||||
Hairy cell leukemia |
|
|
| ||||
Plasma cell myeloma | |||||||
Chronic lymphocytic leukemia / small lymphocytic lymphoma | |||||||
Monoclonal B-cell lymphocytosis | |||||||
B-cell prolymphocytic leukemia | |||||||
Waldenström's macroglubulinemia | |||||||
Monoclonal gammopathy of undetermined significance (MGUS) | |||||||
Heavy chain disease | |||||||
Solitary plasmacytoma of bone | |||||||
Extraosseous plasmacytoma | |||||||
Monoclonal immunoglobulin deposition diseases | |||||||
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) | |||||||
Large B-cell lymphoma with IRF4 rearrangement | |||||||
Primary cutaneous follicle center lymphoma | |||||||
T-cell/histiocyte-rich large B-cell lymphoma | |||||||
Lymphomatoid granulomatosis | |||||||
Primary mediastinal (thymic) large B-cell lymphoma | |||||||
Intravascular large B-cell lymphoma | |||||||
ALK1 large B-cell lymphoma | |||||||
Plasmablastic lymphoma | |||||||
Primary effusion lymphoma | |||||||
High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements | |||||||
T cell lymphoma | Mycosis fungoides / Sézary syndrome |
|
|
|
|||
T-cell granular lymphocytic leukemia |
|
Symptoms of T-cell large granular lymphocyte leukemia may include the following: |
|
|
| ||
Subcutaneous panniculitis-like T-cell lymphoma |
- ↑ Shipp, Margaret A.; Ross, Ken N.; Tamayo, Pablo; Weng, Andrew P.; Kutok, Jeffery L.; Aguiar, Ricardo C.T.; Gaasenbeek, Michelle; Angelo, Michael; Reich, Michael; Pinkus, Geraldine S.; Ray, Tane S.; Koval, Margaret A.; Last, Kim W.; Norton, Andrew; Lister, T. Andrew; Mesirov, Jill; Neuberg, Donna S.; Lander, Eric S.; Aster, Jon C.; Golub, Todd R. (2002). "Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning". Nature Medicine. 8 (1): 68–74. doi:10.1038/nm0102-68. PMID 11786909.
- ↑ Rosenwald, Andreas; Wright, George; Chan, Wing C.; Connors, Joseph M.; Campo, Elias; Fisher, Richard I.; Gascoyne, Randy D.; Muller-Hermelink, H. Konrad; Smeland, Erlend B.; Giltnane, Jena M.; Hurt, Elaine M.; Zhao, Hong; Averett, Lauren; Yang, Liming; Wilson, Wyndham H.; Jaffe, Elaine S.; Simon, Richard; Klausner, Richard D.; Powell, John; Duffey, Patricia L.; Longo, Dan L.; Greiner, Timothy C.; Weisenburger, Dennis D.; Sanger, Warren G.; Dave, Bhavana J.; Lynch, James C.; Vose, Julie; Armitage, James O.; Montserrat, Emilio; et al. (2002). "The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma". New England Journal of Medicine. 346 (25): 1937–47. doi:10.1056/NEJMoa012914. PMID 12075054.
- ↑ Colomo, L.; López-Guillermo, A; Perales, M; Rives, S; Martínez, A; Bosch, F; Colomer, D; Falini, B; Montserrat, E; Campo, E (2002). "Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma". Blood. 101 (1): 78–84. doi:10.1182/blood-2002-04-1286. PMID 12393466.
- ↑ National Cancer Institute. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov
- ↑ Tilly H, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2015; 26: v116-v125
- ↑ National Cancer Institute. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov
- ↑ Korkolopoulou P, Vassilakopoulos T, Milionis V, Ioannou M (2016). "Recent Advances in Aggressive Large B-cell Lymphomas: A Comprehensive Review". Adv Anat Pathol. 23 (4): 202–43. doi:10.1097/PAP.0000000000000117. PMID 27271843.